Skip to main content

Table 1 Baseline characteristics of 382 patients included in the re-analyses of the PRODIGE 9 Trial

From: Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

 

Maintenance group

Control group

Sample size

193

189

Patients characteristics

 Age

  <  65 years old

102 (52.8%)

97 (51.3%)

  ≥ 65 & < 75 years old

59 (30.6%)

58 (30.7%)

  ≥ 75 years old

32 (16.6%)

34 (18.0%)

Women

71 (36.8%)

62 (32.8%)

 WHO performance status (PS)

  0

105 (54.4%)

102 (54.0%)

  1

81 (42.0%)

78 (41.3%)

  2

7 (3.6%)

9 (4.8%)

Alkaline phosphatase >  300 U/L

33 (17.1%)

35 (18.5%)

Leucocytes >  10 × 109

51 (26.4%)

45 (23.8%)

 Localisation

  Left colon

65 (33.7%)

60 (31.7%)

  Right and transverse colon

38 (19.7%)

49 (25.9%)

  Unspecified colon

42 (21.8%)

47 (24.9%)

  Rectum

48 (24.9%)

33 (17.5%)